OKYO OKYO Pharma Ltd

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

January 2025

 

 

Commission File Number: 001-41386

 

 

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

 

 

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

 

On January 31, 2025, OKYO Pharma LTD (the “Company”) issued this 6K announcing today, that it has been notified that the Chief Executive Officer, Gary S. Jacob has purchased 10,000 of the Company’s ordinary shares on NASDAQ at a price of US$1.04 per share. We have also been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 20,000 of the Company’s ordinary shares on NASDAQ at a price of US$1.04 per share. This brings the total shareholding of Mr Cerrone to 9,871,570 shares which is 28.96% of issued share capital.

 

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	OKYO Pharma LTD
Date: January 31, 2025	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

 

 

EXHIBIT INDEX

 

Exhibit No.		Description
99.1		News Announcement, dated January 31, 2025

 

 

Exhibit 99.1

 

 

OKYO Pharma Announces Chairman and CEO Acquire Shares

 

 

London and New York, NY, January 31, 2025 – OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, announced today that it has been notified that the Chief Executive Officer, Gary S. Jacob has purchased 10,000 of the Company’s ordinary shares on NASDAQ at a price of US$1.04 per share.

 

We have also been notified that Panetta Partners Limited, an entity in which Gabriele Cerrone, the Executive Chairman has a beneficial interest, purchased 20,000 of the Company’s ordinary shares on NASDAQ at a price of US$1.04 per share. This brings the total shareholding of Mr Cerrone to 9,871,570 shares which is 28.96% of issued share capital.

 

About OKYO

 

OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of NCP and DED, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat NCP and inflammatory DED. In addition to the completed Phase 2 trial of OK-101 to treat DED patients, OKYO is also currently evaluating OK-101 to treat NCP patients in a Phase 2 trial.

 

Enquiries:

 

OKYO Pharma Limited		Gary S. Jacob, Chief Executive Officer		U.S. 917-497-7560
Business Development & Investor Relations		Paul Spencer		+44 (0)20 7495 2379

 

 

 

 

 

 

---